Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., an Israeli technology company, says that bringing new cancer treatments to market involves a long and difficult process. The many rules that exist in most countries are quite costly to navigate. Small firms often don’t survive the startup process because they run out of money befor they can market their new products.
Sometimes, however, smaller companies create new therapies that are far more advanced than those manufactured by large firms. Dr. Michael Har-Noy, has, with limited funds, designed innovative new drugs that may change cancer treatment permanently. These compounds will hopefully be marketed in the not-too-distant future.
Adjuvant therapy of cancer consists primarily of chemotherapy and radiation treatments. These therapies are quite toxic, resulting in severe side effects and significantly impairing patients’ quality of life. Preliminary studies done by Dr. Michael Har-Noy have shown that immune therapies are far more effective than traditional treatments and exhibit much less toxicity.
Currently, Dr. Michael Har-Noy is working on marketing AlloStimTM, CryoStimTM, and AlloVaxTM, which are proprietary biologic drugs that “wake up” the body’s immune system and assist it in destgroying malignant cells. Preliminary results in of a Phase I/II trial show significant effects of these drugs against many different tumors. Also, these unique compounds apparently have minimal side effects on the patient. Dr. Michael Har-Noy has attained FDA approval in Thailand to begin a randomized Phase II/III trial of AlloStimTM to treat metastatic colon tumors.
These unique compounds being created by Dr. Michael Har-Noy seem to be much more efficacious than traditional chemotherapeutic agents. They may spawn an entire new industry in cancer therapy.